Recordati : Le groupe prend de l’avance en prévision d’un S2 moins favorable
>Un T2 marqué par la bonne maîtrise des OPEX - Recordati a publié en fin de semaine dernière des chiffres T2 de bonne facture et ceci malgré un effet de base moins favorable qu’au T1 sur son business SPC conjugué à un impact changes délétère induit par la dévaluation de livre turque (impact de -30 M€ dont la grande partie au T2). Les ventes ont progressé de 4.2% sur la période (en ligne avec le Cs) à 493 M€ toujours tirées par le business SPC ainsi que les maladies r...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.